Autoantibody Profiling for Serological Detection of Head and Neck Cancer
Autoantibody Profiling for Serological Detection of Head and Neck Cancer
批准号:
7671946
负责人:
Nada H Khattar
金额:
$21.78万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2010-06-30
关键词:
Advanced DevelopmentAffectAgreementAlcoholsApplications GrantsAutoantibodiesBacteriophagesBindingBioinformaticsBiological AssayBiological MarkersBlindedBloodBlood TestsBlood specimenCaringClassificationClinicalCollaborationsConsultCurative SurgeryDataDetectionDevelopmentDiagnosisDiagnosticDiagnostic Neoplasm StagingDiseaseDoctor of PhilosophyEarly DiagnosisFailureFeasibility StudiesFloodsFundingGrantHeadHead and Neck CancerHead and Neck Squamous Cell CarcinomaImmuneImmunoassayKentuckyLegal patentLesionLicensingLung NeoplasmsMalignant neoplasm of lungMediationMedicalModalityNon-Small-Cell Lung CarcinomaPatientsPeptidesPersonsPhage DisplayPhasePhysiciansPlasmaPopulationPremalignantProcessProtein MicrochipsProteomicsPublicationsPublishingRightsRiskSamplingScreening procedureSerologic testsSerologicalSerumSmall Business Innovation Research GrantSmokerSpecificityStagingSymptomsTechniquesTechnologyTestingTherapeuticTobaccoTrainingTranslationsUniversitiesUpper armValidationWorkX-Ray Computed Tomographybasecancer diagnosiscosthigh riskinnovative technologiesinterestmortalitynoveloutcome forecastpatient populationpublic health relevancetooltumorvalidation studies
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): SBIR grant support is being sought by 20/20 GeneSystems, Inc. (20/20), a small biotech company, to help us advance what we believe will become the first blood test to be routinely employed to aid in the early detection of head and neck cancer. Despite recent advances in both diagnostic and therapeutic modalities, long-term prognosis for patients affected by advanced stage head and neck squamous cell carcinoma (HNSCC) remains dismal with 5-year survival less than 40%. This grim prognosis is in distinct contrast to the more than 80% chance of cure for those patients who present with early stage cancer. Unfortunately, more than two-third of patients with HNSCC are diagnosed only after the disease is advanced. Failure to diagnose this cancer early is mainly attributed to the unavailability of a screening test for high risk patients as well as frequent misdiagnosis of early stage cancer by primary physicians. An autoantibody immunoassay for head and neck squamous cell carcinoma (HNSCC) is expected to become a novel non-invasive tool for early diagnosis. Our long term strategy, which would become the subject of a Phase II SBIR grant application should Phase I work be successful, is to develop a "tobacco user's chip" to screen for both HNSCC and lung cancer in one blood sample, because current and former smokers are at high risk for both diseases. The serological test should have a significant impact on the quality of medical care for persons at risk, particularly for over 20% of the US population who are users of tobacco and/or alcohol products. PUBLIC HEALTH RELEVANCE: A blood test for early detection of head and neck cancer could provide a cost-effective screening approach when applied to presently known high risk groups, who are: users of tobacco and/or alcohol, the immune-compromised, and those with premalignant lesions. It would enable a viable strategy for reducing the severe mortality rate of this disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Profiling Autoantibodies in Non-small Cell Lung Cancer with Fusion Protein-Peptid
-
批准号:7748317
-
项目类别:
-
资助金额:$18.39万
-
财政年份:2009
-
负责人:Nada H Khattar
-
依托单位:
Peptide Array for Profiling of Autoantibodies in Non-small Cell Lung Cancer
-
批准号:7408695
-
项目类别:
-
资助金额:$16.53万
-
财政年份:2007
-
负责人:Nada H Khattar
-
依托单位:
海外基金